Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Leukemia
|
August 15, 2000
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
K Naito, A Takeshita, K Shigeno, et al.
Leukemia
|
May 3, 2002
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers
H Matsui, A Takeshita, K Naito, et al.
The Prostate
|
June 15, 1997
Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity in human prostatic carcinoma
H Shiina, M Igawa, K Shigeno, et al.
The International Journal of Artificial Organs
|
February 24, 2001
Regeneration of the junctional epithelium and connective tissue after transplantation of detergent-processed allo-teeth
M Inoue, T Nakamura, K Shigeno, et al.
Leukemia
|
May 28, 2005
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells
A Takeshita, K Shinjo, K Naito, et al.
Leukemia
|
March 21, 2003
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells
A Takeshita, K Shinjo, K Naito, et al.
The International Journal of Artificial Organs
|
December 19, 2002
Regenerative repair of the mandible using a collagen sponge containing TGF-beta1
K Shigeno, T Nakamura, M Inoue, et al.
Leukemia
|
April 17, 2009
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
A Takeshita, N Yamakage, K Shinjo, et al.
Leukemia
|
April 18, 2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring
K Ohnishi, H Yoshida, K Shigeno, et al.
Annals of Internal Medicine
|
December 5, 2000
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
K Ohnishi, H Yoshida, K Shigeno, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Leukemia
|
August 15, 2000
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
K Naito, A Takeshita, K Shigeno, et al.
Leukemia
|
May 3, 2002
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers
H Matsui, A Takeshita, K Naito, et al.
The Prostate
|
June 15, 1997
Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity in human prostatic carcinoma
H Shiina, M Igawa, K Shigeno, et al.
The International Journal of Artificial Organs
|
February 24, 2001
Regeneration of the junctional epithelium and connective tissue after transplantation of detergent-processed allo-teeth
M Inoue, T Nakamura, K Shigeno, et al.
Leukemia
|
May 28, 2005
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells
A Takeshita, K Shinjo, K Naito, et al.
Leukemia
|
March 21, 2003
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells
A Takeshita, K Shinjo, K Naito, et al.
The International Journal of Artificial Organs
|
December 19, 2002
Regenerative repair of the mandible using a collagen sponge containing TGF-beta1
K Shigeno, T Nakamura, M Inoue, et al.
Leukemia
|
April 17, 2009
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
A Takeshita, N Yamakage, K Shinjo, et al.
Leukemia
|
April 18, 2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring
K Ohnishi, H Yoshida, K Shigeno, et al.
Annals of Internal Medicine
|
December 5, 2000
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
K Ohnishi, H Yoshida, K Shigeno, et al.
Page
of 7